Literature DB >> 9257145

Intravenous line infection due to Ochrobactrum anthropi (CDC Group Vd) in a normal host.

M V Gill1, H Ly, M Mueenuddin, P E Schoch, B A Cunha.   

Abstract

Ochrobactrum anthropi, formerly known as Achromobacter species (CDC group Vd), is an aerobic, gram-negative bacillus widely distributed in aquatic environments. Most important, it has been implicated as a cause of intravenous line infection in immunocompromised hosts with solid tumors or hematologic malignancies. Trimethoprim-sulfamethoxazole and aminoglycosides are usually active against O. anthropi, but this organism is usually resistant to beta-lactam antibiotics. Because O. anthropi is a low-virulence organism, patients with intravenous-line infections have been cured without removal of the intravenous catheter. We describe a case of intravenous-line infection in a normal host that was successfully resolved alter catheter removal.

Entities:  

Mesh:

Year:  1997        PMID: 9257145     DOI: 10.1016/s0147-9563(97)90092-3

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  10 in total

Review 1.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Molecular characterization of chromosomal class C beta-lactamase and its regulatory gene in Ochrobactrum anthropi.

Authors:  D Nadjar; R Labia; C Cerceau; C Bizet; A Philippon; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Brucella abortus and its closest phylogenetic relative, Ochrobactrum spp., differ in outer membrane permeability and cationic peptide resistance.

Authors:  J Velasco; J A Bengoechea; K Brandenburg; B Lindner; U Seydel; D González; U Zähringer; E Moreno; I Moriyón
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Alterations of lung microbiota in a mouse model of LPS-induced lung injury.

Authors:  Valeriy Poroyko; Fanyong Meng; Angelo Meliton; Taras Afonyushkin; Alexander Ulanov; Ekaterina Semenyuk; Omar Latif; Vera Tesic; Anna A Birukova; Konstantin G Birukov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-08       Impact factor: 5.464

Review 5.  Prosthetic mitral valve endocarditis due to Ochrobactrum anthropi: case report.

Authors:  M P Romero Gómez; A M Peinado Esteban; J A Sobrino Daza; J A Sáez Nieto; D Alvarez; P Peña García
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

6.  Multilocus sequence typing supports the hypothesis that Ochrobactrum anthropi displays a human-associated subpopulation.

Authors:  Sara Romano; Fabien Aujoulat; Estelle Jumas-Bilak; Agnès Masnou; Jean-Luc Jeannot; Enevold Falsen; Hélène Marchandin; Corinne Teyssier
Journal:  BMC Microbiol       Date:  2009-12-18       Impact factor: 3.605

Review 7.  Pelvic abscess due to Ochrobactrum intermedium [corrected] in an immunocompetent host: case report and review of the literature.

Authors:  Sagar A Vaidya; Diane M Citron; Marjorie B Fine; Georgette Murakami; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  Clinical characteristics of Ochrobactrum anthropi bacteremia.

Authors:  Hideharu Hagiya; Kouhei Ohnishi; Miyako Maki; Naoto Watanabe; Tomoko Murase
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

9.  Onchycobacter anthropi Pyomyositis in Immunocompetent Patient: Case Report.

Authors:  Senthil Loganathan; Adnan Qamar; Thyagarajan Umashankar; Gokul Raj Dhanarajan
Journal:  J Orthop Case Rep       Date:  2022-03

10.  The differential interaction of Brucella and ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens.

Authors:  Elías Barquero-Calvo; Raquel Conde-Alvarez; Carlos Chacón-Díaz; Lucía Quesada-Lobo; Anna Martirosyan; Caterina Guzmán-Verri; Maite Iriarte; Mateja Mancek-Keber; Roman Jerala; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno; Esteban Chaves-Olarte
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.